Opendata, web and dolomites

SmartMarker SIGNED

SmartMarker - Clinical Validation of Biomarkers by Smart Data Analyses

Total Cost €


EC-Contrib. €






Project "SmartMarker" data sheet

The following table provides information about the project.

Averbis GmbH 

Organization address
postcode: 79106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme /SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Averbis GmbH DE (FREIBURG IM BREISGAU) coordinator 50˙000.00


 Project objective

The overall goal of SmartMarker is the development of a commercial infrastructure that allows to transform heterogeneous patient health information, typically stored in multiple clinical and health IT systems, into standardized, comparable, consistent, and queryable data. The ultimate goal of this infrastructure is to conduct retrospective clinical biomarker validation studies and to foster effective treatments to marker-defined patient subgroups. Exploitation of the electronic medical records will allow pragmatic and low cost, but still robust and appropriate analytical retrospective study methods to measure the prognostic and predictive outcome of clinical biomarkers. SmartMarker will dramatically ease the process of clinical biomarker validation in the cardiology domain. Ischemic heart disease is the leading cause of death in the developed world. The primary biomarker used to identify patients at high risk of sudden death is the ejection fraction. Brain natriuretic peptide is a useful biomarker for predicting the presence of heart failure, risk of readmission and mortality. However, only few biomarkers have been rigorously validated in clinical routine, and few of these markers have been integrated for identifying high risk cohorts in routine clinical practice. This led to a widening implementation gap between recommendations from national and international guidelines and actual routine clinical practice. With SmartMarker we want to close this gap and achieve best-possible outcomes for the patients. We will validate the link between already existing clinical biomarkers in cardiology that are collected on a daily basis in the clinical routine and pertinent clinical endpoints. Finally, we bring forward effective treatments to marker-defined patient subgroups.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTMARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMARTMARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

BIOSIM (2017)

Accelerating the commercialisation of a disruptive analytical technology which enables thebiopharmaceutical industry to manufacture drugs faster, cheaper and with greater regulatoryconfidence

Read More  

ABC-S (2018)

Acoustic Blood Cells Sorter

Read More  

SDS-OmiProbe (2017)

Revolutionary opto-biological methodology for aggressive HER2 cancer

Read More